Literature DB >> 21397859

The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma.

Shwetal Mehta1, Emmanuelle Huillard, Santosh Kesari, Cecile L Maire, Diane Golebiowski, Emily P Harrington, John A Alberta, Michael F Kane, Matthew Theisen, Keith L Ligon, David H Rowitch, Charles D Stiles.   

Abstract

High-grade gliomas are notoriously insensitive to radiation and genotoxic drugs. Paradoxically, the p53 gene is structurally intact in the majority of these tumors. Resistance to genotoxic modalities in p53-positive gliomas is generally attributed to attenuation of p53 functions by mutations of other components within the p53 signaling axis, such as p14(Arf), MDM2, and ATM, but this explanation is not entirely satisfactory. We show here that the central nervous system (CNS)-restricted transcription factor Olig2 affects a key posttranslational modification of p53 in both normal and malignant neural progenitors and thereby antagonizes the interaction of p53 with promoter elements of multiple target genes. In the absence of Olig2 function, even attenuated levels of p53 are adequate for biological responses to genotoxic damage.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21397859      PMCID: PMC3070398          DOI: 10.1016/j.ccr.2011.01.035

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  71 in total

1.  Cancer stem cells: Here, there, everywhere?

Authors:  Connie J Eaves
Journal:  Nature       Date:  2008-12-04       Impact factor: 49.962

2.  Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen.

Authors:  M D Prados; M S Edwards; J Rabbitt; K Lamborn; R L Davis; V A Levin
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

3.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

4.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

5.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.

Authors:  L A Donehower; M Harvey; B L Slagle; M J McArthur; C A Montgomery; J S Butel; A Bradley
Journal:  Nature       Date:  1992-03-19       Impact factor: 49.962

Review 6.  The cancer stem cell hypothesis: a work in progress.

Authors:  Brenton Thomas Tan; Christopher Yongchul Park; Laurie Elizabeth Ailles; Irving L Weissman
Journal:  Lab Invest       Date:  2006-10-30       Impact factor: 5.662

7.  The basic helix-loop-helix factor olig2 is essential for the development of motoneuron and oligodendrocyte lineages.

Authors:  Hirohide Takebayashi; Yoko Nabeshima; Shosei Yoshida; Osamu Chisaka; Kazuhiro Ikenaka; Yo-ichi Nabeshima
Journal:  Curr Biol       Date:  2002-07-09       Impact factor: 10.834

8.  Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271.

Authors:  Alexander D Boiko; Olga V Razorenova; Matt van de Rijn; Susan M Swetter; Denise L Johnson; Daphne P Ly; Paris D Butler; George P Yang; Benzion Joshua; Michael J Kaplan; Michael T Longaker; Irving L Weissman
Journal:  Nature       Date:  2010-07-01       Impact factor: 49.962

9.  The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.

Authors:  Keith L Ligon; John A Alberta; Alvin T Kho; Jennifer Weiss; Mary R Kwaan; Catherine L Nutt; David N Louis; Charles D Stiles; David H Rowitch
Journal:  J Neuropathol Exp Neurol       Date:  2004-05       Impact factor: 3.685

10.  Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.

Authors:  G Reifenberger; L Liu; K Ichimura; E E Schmidt; V P Collins
Journal:  Cancer Res       Date:  1993-06-15       Impact factor: 12.701

View more
  86 in total

1.  Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.

Authors:  Adam L Green; Shakti H Ramkissoon; Dilara McCauley; Kristen Jones; Jennifer A Perry; Jessie Hao-Ru Hsu; Lori A Ramkissoon; Cecile L Maire; Benjamin Hubbell-Engler; David S Knoff; Sharon Shacham; Keith L Ligon; Andrew L Kung
Journal:  Neuro Oncol       Date:  2014-11-02       Impact factor: 12.300

2.  Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy.

Authors:  Yayoi Kinoshita; Tamara Kalir; Jamal Rahaman; Peter Dottino; D Stave Kohtz
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

3.  Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF-β Pathway.

Authors:  Shiv K Singh; Roberto Fiorelli; Robert Kupp; Sindhu Rajan; Emily Szeto; Costanza Lo Cascio; Cecile L Maire; Yu Sun; John A Alberta; Jennifer M Eschbacher; Keith L Ligon; Michael E Berens; Nader Sanai; Shwetal Mehta
Journal:  Cell Rep       Date:  2016-07-07       Impact factor: 9.423

4.  Olig2-Dependent Reciprocal Shift in PDGF and EGF Receptor Signaling Regulates Tumor Phenotype and Mitotic Growth in Malignant Glioma.

Authors:  Fanghui Lu; Ying Chen; Chuntao Zhao; Haibo Wang; Danyang He; Lingli Xu; Jincheng Wang; Xuelian He; Yaqi Deng; Ellen E Lu; Xue Liu; Ravinder Verma; Hong Bu; Rachid Drissi; Maryam Fouladi; Anat O Stemmer-Rachamimov; Dennis Burns; Mei Xin; Joshua B Rubin; El Mustapha Bahassi; Peter Canoll; Eric C Holland; Q Richard Lu
Journal:  Cancer Cell       Date:  2016-05-09       Impact factor: 31.743

5.  Development: directing development through phosphorylation.

Authors:  Darran Yates
Journal:  Nat Rev Neurosci       Date:  2011-04-13       Impact factor: 34.870

6.  A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas.

Authors:  Yu Sun; John A Alberta; Catherine Pilarz; David Calligaris; Emily J Chadwick; Shakti H Ramkissoon; Lori A Ramkissoon; Veronica Matia Garcia; Emanuele Mazzola; Liliana Goumnerova; Michael Kane; Zhan Yao; Mark W Kieran; Keith L Ligon; William C Hahn; Levi A Garraway; Neal Rosen; Nathanael S Gray; Nathalie Y Agar; Sara J Buhrlage; Rosalind A Segal; Charles D Stiles
Journal:  Neuro Oncol       Date:  2017-06-01       Impact factor: 12.300

7.  A frightening thought: Neuronal activity enhances tumor growth.

Authors:  Emily G Thompson; Harald Sontheimer
Journal:  Cell Res       Date:  2015-06-02       Impact factor: 25.617

8.  Specific ablation of Nampt in adult neural stem cells recapitulates their functional defects during aging.

Authors:  Liana R Stein; Shin-ichiro Imai
Journal:  EMBO J       Date:  2014-05-08       Impact factor: 11.598

9.  Neuronal Activity Promotes Glioma Growth through Neuroligin-3 Secretion.

Authors:  Humsa S Venkatesh; Tessa B Johung; Viola Caretti; Alyssa Noll; Yujie Tang; Surya Nagaraja; Erin M Gibson; Christopher W Mount; Jai Polepalli; Siddhartha S Mitra; Pamelyn J Woo; Robert C Malenka; Hannes Vogel; Markus Bredel; Parag Mallick; Michelle Monje
Journal:  Cell       Date:  2015-04-23       Impact factor: 41.582

10.  Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells.

Authors:  Jun Fu; Dimpy Koul; Jun Yao; Shuzhen Wang; Ying Yuan; Howard Colman; Erik P Sulman; Frederick F Lang; W K Alfred Yung
Journal:  Cancer Res       Date:  2013-03-14       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.